Related Experiment Video
Updated: Feb 27, 2026
07:51
The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
Published on: June 1, 2019
21.7K
Completion lymph node dissection in patients with melanoma and positive sentinel lymph node biopsy
1Jacqueline Link practices melanoma surgical oncology at Brigham and Women's Hospital/Dana Farber Cancer Institute in Boston, Mass. The author has disclosed no potential conflicts of interest, financial or otherwise.
Summary
Completion lymph node dissection (CLND) for melanoma is controversial. While extensive, it offers survival benefits for select patients, warranting a review of current treatment guidelines.
Area of Science:
- Oncology
- Surgical Oncology
- Dermatology
Background:
- Melanoma is an aggressive skin cancer with significant morbidity and mortality.
- Current guidelines recommend sentinel lymph node biopsy followed by completion lymph node dissection (CLND) for intermediate-thickness melanomas with positive nodes.
- The recommendation for CLND is debated due to limited supporting data and the procedure's associated risks.
Purpose of the Study:
- To review the procedure and current recommendations for completion lymph node dissection in melanoma treatment.
- To evaluate the risks and benefits of CLND in the context of melanoma management.
Main Methods:
- Literature review of studies on sentinel lymph node biopsy and completion lymph node dissection for melanoma.
- Analysis of current clinical guidelines and expert opinions regarding CLND.
Main Results:
- Completion lymph node dissection (CLND) is a significant surgery with potential complications.
- The survival benefit of CLND is modest but may outweigh procedural risks in patients with low surgical risk and no comorbidities.
- Limited data currently exists to definitively support the widespread recommendation of CLND.
Conclusions:
- Completion lymph node dissection (CLND) for melanoma remains controversial due to a balance of modest survival benefits against surgical risks.
- The decision to perform CLND should be individualized based on patient comorbidities and surgical risk assessment.
- Further research is needed to clarify the precise role and indications for CLND in melanoma treatment.
